publicações selecionadas
- Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2
- 
                Impact of Distinct Therapies on Antibody Response to              SARS¿CoV ¿2 Vaccine in Systemic Lupus Erythematosus
- A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group
- 
                Physical Activity and Antibody Persistence 6 Months after the Second Dose of              CoronaVac in Immunocompromised Patients
- Estudo prospectivo de um ano da condução nervosa na neuropatia induzida pela talidomida no lúpus eritematoso: incidência, efeito ?coasting? e níveis plasmáticos do fármaco.
- Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine
- SARS-CoV-2 vaccine in patients with systemic sclerosis: Impact of disease subtype and therapy
- One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels
- Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study
- Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
- Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
- Interaction of TNFi and conventional synthetic DMARD in SARS-COV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis
- Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
- Inactivated SARS-CoV-2 vaccine in primary Sjögren?s syndrome: humoral response, safety, and effects on disease activity
- Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area
- Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome
- Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases
- Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis
- Effect of an Exercise Bout Prior to the Booster Dose of an Inactivated SARS-CoV-2 Vaccine on Immunogenicity in Immunocompromised Patients
- Influenza A/Singapore (H3N2) component vaccine in systemic lupus erythematosus: A distinct pattern of immunogenicity
- Association between physical activity and immunogenicity of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseases
- Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial
- Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients
- Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring
- Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: immunogenicity, safety, antibody decay and the booster dose
- Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial




